Skip to main content
Erschienen in: Tumor Biology 12/2014

01.12.2014 | Research Article

CD109 is a potential target for triple-negative breast cancer

verfasst von: Ji Tao, Hongbin Li, Qingwei Li, Yu Yang

Erschienen in: Tumor Biology | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to explore the expression of CD109 in breast cancer stem cells and the relationship between CD109 protein and clinicopathological characteristics of breast cancer. CD44+/CD24− tumor cells (CSCs) were selected by flow cytometry. The protein expression of CD109 was analyzed by immunohistochemistry staining, and the relationship between CD109 and clinicopathological parameters of breast cancer was determined. CD109 positively regulated the proliferation of breast CSCs in vitro, and CD109 protein expression was significantly higher in triple-negative breast cancer (TNBC) compared to non-TNBC (63.78 vs. 3.71 %, P = 0.001). Moreover, CD109 protein expression was related to the histological grade of breast cancer (P = 0.015), whereas age (P = 0.731), tumor size (P = 0.995), clinical stage (P = 0.644), and lymph node metastasis (P = 0.924) were not. In the logistic regression model, histological grade (P = 0.001) and molecular type (P = 0.001) were significantly related to CD109 expression. The patients with high expression of CD109 protein had significantly poorer postoperative disease-specific survival than those with no or low expression of CD109 protein (P = 0.001). In the Cox regression, CD109 was an independent prognostic factor (P = 0.001). CD109 is highly expressed in TNBC and is a potential biomarker for the initiation, progression, and differentiation of breast cancer tumors.
Literatur
1.
Zurück zum Zitat Desantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.CrossRef Desantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62.CrossRef
2.
Zurück zum Zitat Wright MH, Calcagno AM, Salcido CD, et al. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008;10:R10.CrossRef Wright MH, Calcagno AM, Salcido CD, et al. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008;10:R10.CrossRef
3.
Zurück zum Zitat Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007;356:217–26.CrossRef Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007;356:217–26.CrossRef
4.
Zurück zum Zitat Gao N, Xu H, Liu C, Xu H, Chen G, Wang X, Li Y, Wang Y. Nestin: predicting specific survival factors for breast cancer. Tumour Biol. 2014 Gao N, Xu H, Liu C, Xu H, Chen G, Wang X, Li Y, Wang Y. Nestin: predicting specific survival factors for breast cancer. Tumour Biol. 2014
5.
Zurück zum Zitat Xu D, Xu H, Ren Y, Liu C, Wang X, Zhang H, et al. Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS One. 2012;7(10):e46670.CrossRef Xu D, Xu H, Ren Y, Liu C, Wang X, Zhang H, et al. Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS One. 2012;7(10):e46670.CrossRef
6.
Zurück zum Zitat Liu CG, Lu Y, Wang BB, Zhang YJ, Zhang RS, Lu Y, et al. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg. 2011;253(6):1165–71.CrossRef Liu CG, Lu Y, Wang BB, Zhang YJ, Zhang RS, Lu Y, et al. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg. 2011;253(6):1165–71.CrossRef
7.
Zurück zum Zitat Emori M, Tsukahara T, Murase M, Kano M, Murata K, Takahashi A, et al. High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma. PLoS One. 2013;8(12):e84187.CrossRef Emori M, Tsukahara T, Murase M, Kano M, Murata K, Takahashi A, et al. High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma. PLoS One. 2013;8(12):e84187.CrossRef
8.
Zurück zum Zitat Cuppini L, Calleri A, Bruzzone MG, Prodi E, Anghileri E, Pellegatta S, et al. Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS One. 2013;8(9):e74345.CrossRef Cuppini L, Calleri A, Bruzzone MG, Prodi E, Anghileri E, Pellegatta S, et al. Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS One. 2013;8(9):e74345.CrossRef
9.
Zurück zum Zitat COTZIAS GC, BORG DC, SELLECK B. Virtual absence of turnover in cadmium metabolism: Cd109 studies in the mouse. Am J Physiol. 1961;201:927–30.CrossRef COTZIAS GC, BORG DC, SELLECK B. Virtual absence of turnover in cadmium metabolism: Cd109 studies in the mouse. Am J Physiol. 1961;201:927–30.CrossRef
10.
Zurück zum Zitat Hockla A, Radisky DC, Radisky ES. Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. Breast Cancer Res Treat. 2010;124(1):27–38.CrossRef Hockla A, Radisky DC, Radisky ES. Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. Breast Cancer Res Treat. 2010;124(1):27–38.CrossRef
11.
Zurück zum Zitat Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–8.CrossRef Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–8.CrossRef
12.
Zurück zum Zitat Ozbay PÖ, Ekinci T, Yiǧit S, Yavuzcan A, Uysal S, Soylu F, et al. Investigation of prognostic significance of CD109 expression in women with vulvar squamous cell carcinoma. Oncol Targets Ther. 2013;6:621–7. Ozbay PÖ, Ekinci T, Yiǧit S, Yavuzcan A, Uysal S, Soylu F, et al. Investigation of prognostic significance of CD109 expression in women with vulvar squamous cell carcinoma. Oncol Targets Ther. 2013;6:621–7.
13.
Zurück zum Zitat Man XY, Finnson KW, Baron M, Philip A. CD109, a TGF-β co-receptor, attenuates extracellular matrix production in scleroderma skin fibroblasts. Arthritis Res Ther. 2012;14(3):R144.CrossRef Man XY, Finnson KW, Baron M, Philip A. CD109, a TGF-β co-receptor, attenuates extracellular matrix production in scleroderma skin fibroblasts. Arthritis Res Ther. 2012;14(3):R144.CrossRef
14.
Zurück zum Zitat Bizet AA, Tran-Khanh N, Saksena A, Liu K, Buschmann MD, Philip A. CD109-mediated degradation of TGF-β receptors and inhibition of TGF-β responses involve regulation of SMAD7 and Smurf2 localization and function. J Cell Biochem. 2012;113(1):238–46.CrossRef Bizet AA, Tran-Khanh N, Saksena A, Liu K, Buschmann MD, Philip A. CD109-mediated degradation of TGF-β receptors and inhibition of TGF-β responses involve regulation of SMAD7 and Smurf2 localization and function. J Cell Biochem. 2012;113(1):238–46.CrossRef
15.
Zurück zum Zitat Wang Y, Inger M, Jiang H, Tenenbaum H, Glogauer M. CD109 plays a role in osteoclastogenesis. PLoS One. 2013;8(4):e61213.CrossRef Wang Y, Inger M, Jiang H, Tenenbaum H, Glogauer M. CD109 plays a role in osteoclastogenesis. PLoS One. 2013;8(4):e61213.CrossRef
16.
Zurück zum Zitat Hagikura M, Murakumo Y, Hasegawa M, Jijiwa M, Hagiwara S, Mii S, et al. Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression. Pathol Int. 2010;60(11):735–43.CrossRef Hagikura M, Murakumo Y, Hasegawa M, Jijiwa M, Hagiwara S, Mii S, et al. Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression. Pathol Int. 2010;60(11):735–43.CrossRef
17.
Zurück zum Zitat Ohshima Y, Yajima I, Kumasaka MY, Yanagishita T, Watanabe D, Takahashi M, et al. CD109 expression levels in malignant melanoma. J Dermatol Sci. 2010;57(2):140–2.CrossRef Ohshima Y, Yajima I, Kumasaka MY, Yanagishita T, Watanabe D, Takahashi M, et al. CD109 expression levels in malignant melanoma. J Dermatol Sci. 2010;57(2):140–2.CrossRef
18.
Zurück zum Zitat Hagiwara S, Murakumo Y, Sato T, Shigetomi T, Mitsudo K, Tohnai I, et al. Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. Cancer Sci. 2008;99(10):1916–23.PubMed Hagiwara S, Murakumo Y, Sato T, Shigetomi T, Mitsudo K, Tohnai I, et al. Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. Cancer Sci. 2008;99(10):1916–23.PubMed
19.
Zurück zum Zitat Hasegawa M, Moritani S, Murakumo Y, Sato T, Hagiwara S, Suzuki C, et al. CD109 expression in basal-like breast carcinoma. Pathol Int. 2008;58(5):288–94.CrossRef Hasegawa M, Moritani S, Murakumo Y, Sato T, Hagiwara S, Suzuki C, et al. CD109 expression in basal-like breast carcinoma. Pathol Int. 2008;58(5):288–94.CrossRef
Metadaten
Titel
CD109 is a potential target for triple-negative breast cancer
verfasst von
Ji Tao
Hongbin Li
Qingwei Li
Yu Yang
Publikationsdatum
01.12.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 12/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2509-5

Weitere Artikel der Ausgabe 12/2014

Tumor Biology 12/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.